Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly 4Q Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Lilly 4Q Results

Revenues up 45% and earnings up 101% driven by Mounjaro and Zepbound.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma
Lilly

Image courtesy of Lilly.

Lilly

4Q Revenues: $13.5 billion (45%)

4Q Earnings: $4.4 billion (+101%)

FY Revenues: $45.0 billion (32%)

FY Earnings: $10.6 billion (+102%)

Comments: Growth in the quarter was driven by Mounjaro, with sales up 60% to $3.5 billion, and Zepbound, with sales of $1.9 billion. New Products revenue, which consists of Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh and Zepbound, grew by $3.15 billion to $5.64 billion, led by Zepbound and Mounjaro.

Growth Products revenue, which consists of Cyramza, Emgality, Jardiance, Olumiant, Retevmo, Taltz, Trulicity, Tyvyt and Verzenio, increased 13% to $5.95 billion, driven by Verzenio and Jardiance, partially offset by lower Trulicity sales. Verzenio sales were $1.56 billion, up 36%. Jardiance sales were up 50% to $1.2 billion. Trulicity sales were down 25% to $1.25 billion.

In the quarter, the FDA approved of Zepbound for a new indication as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics